open access

Ahead of Print
Research paper
Published online: 2023-04-05
Get Citation

Diagnostic potential of microRNAs Mi 517 and Mi 526 as biomarkers in the detection of hypertension and preeclampsia in the first trimester

Adrianna Kondracka1, Bartosz Kondracki2, Ilona Jaszczuk3, Jakub Staniczek4, Wojciech Kwasniewski5, Agata Filip3, Anna Kwasniewska1
Affiliations
  1. Department of Obstetrics and Pathology of Pregnancy, Medical University of Lublin, Poland
  2. Department of Cardiology, Medical University of Lublin, Poland
  3. Department of Cancer Genetics with Cytogenetic Laboratory, Medical University of Lublin, Poland
  4. Department of Gynecology, Obstetrics and Gynecologic Oncology, Medical University of Silesia, Katowice, Poland
  5. Department of Gynecology and Gynecologic Oncology, Medical University of Lublin, Poland

open access

Ahead of Print
ORIGINAL PAPERS Obstetrics
Published online: 2023-04-05

Abstract

Objectives: MicroRNAs have been observed to play a major role in various physiological processes, for instance, programmed cell death, cell division, pregnancy development, and proliferation. With the help of profiling of microRNAs in the serum of pregnant women, it is possible to link alterations in their concentration to the emergence of gestational problems. The aim of the study was to evaluate the diagnostic potential of MicroRNAs Mi 517 and Mi 526 as biomarkers in the detection of hypertension and preeclampsia. 

Material and methods: The study considered 53 patients who are in their first trimester of a singleton pregnancy. Participants have been divided into two study groups, one group with normal pregnancy and another group having the risk of developing preeclampsia or who developed hypertension or preeclampsia during follow-up constitute the study group. In order to collect data associated with circulating miRNAs in serum, blood samples have been collected from the participants of the study.  

Results: Based on the univariate regression model, increased expression of Mi 517 and 526 and parity status (primapara/multipara) has been obtained. The multivariate logistic analysis shows that independent risk factors for hypertension or preeclampsia are the presence of an R527 and being a primipara.

Conclusions: The study's findings have revealed that R517s and R526s act as major indicative biomarkers in the first trimester for the detection of hypertension and preeclampsia. The circulating C19MC MicroRNA was examined as a potential early indicator of preeclampsia and hypertension in pregnant individuals.

Abstract

Objectives: MicroRNAs have been observed to play a major role in various physiological processes, for instance, programmed cell death, cell division, pregnancy development, and proliferation. With the help of profiling of microRNAs in the serum of pregnant women, it is possible to link alterations in their concentration to the emergence of gestational problems. The aim of the study was to evaluate the diagnostic potential of MicroRNAs Mi 517 and Mi 526 as biomarkers in the detection of hypertension and preeclampsia. 

Material and methods: The study considered 53 patients who are in their first trimester of a singleton pregnancy. Participants have been divided into two study groups, one group with normal pregnancy and another group having the risk of developing preeclampsia or who developed hypertension or preeclampsia during follow-up constitute the study group. In order to collect data associated with circulating miRNAs in serum, blood samples have been collected from the participants of the study.  

Results: Based on the univariate regression model, increased expression of Mi 517 and 526 and parity status (primapara/multipara) has been obtained. The multivariate logistic analysis shows that independent risk factors for hypertension or preeclampsia are the presence of an R527 and being a primipara.

Conclusions: The study's findings have revealed that R517s and R526s act as major indicative biomarkers in the first trimester for the detection of hypertension and preeclampsia. The circulating C19MC MicroRNA was examined as a potential early indicator of preeclampsia and hypertension in pregnant individuals.

Get Citation

Keywords

circulating microRNA; microRNAs; hypertension; biomarkers; pregnant women; pregnancy

About this article
Title

Diagnostic potential of microRNAs Mi 517 and Mi 526 as biomarkers in the detection of hypertension and preeclampsia in the first trimester

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2023-04-05

Page views

394

Article views/downloads

250

DOI

10.5603/GP.a2023.0036

Pubmed

37042323

Keywords

circulating microRNA
microRNAs
hypertension
biomarkers
pregnant women
pregnancy

Authors

Adrianna Kondracka
Bartosz Kondracki
Ilona Jaszczuk
Jakub Staniczek
Wojciech Kwasniewski
Agata Filip
Anna Kwasniewska

References (16)
  1. Kondracka A, Jaszczuk I, Koczkodaj D, et al. Blood serum microRNA profiles of pregnant women as biomarkers of pre-eclampsia evaluation. Journal of Pre-Clinical and Clinical Research. 2020; 14(4): 174–177.
  2. Schiesser M, Holzgreve W, Lapaire O, et al. Sirenomelia, the mermaid syndrome--detection in the first trimester. Prenat Diagn. 2003; 23(6): 493–495.
  3. Park HJ, Shim SS, Cha DH. Combined Screening for Early Detection of Pre-Eclampsia. Int J Mol Sci. 2015; 16(8): 17952–17974.
  4. Leslie MS, Briggs LA. Preeclampsia and the Risk of Future Vascular Disease and Mortality: A Review. J Midwifery Womens Health. 2016; 61(3): 315–324.
  5. Duley L. Pre-eclampsia and the hypertensive disorders of pregnancy. Br Med Bull. 2003; 67: 161–176.
  6. Tan MY, Syngelaki A, Poon LC, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2018; 52(2): 186–195.
  7. Vickers NJ. Animal Communication: When I'm Calling You, Will You Answer Too? Curr Biol. 2017; 27(14): R713–R715.
  8. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9): e3148.
  9. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011; 80(2): 193–208.
  10. Zhao G, Zhou X, Chen S, et al. Differential expression of microRNAs in decidua-derived mesenchymal stem cells from patients with pre-eclampsia. J Biomed Sci. 2014; 21(1): 81.
  11. Pantham P, Soncin F, Zhang-Rutledge K, et al. Innovations in Placental Pathology. Benirschke's Pathology of the Human Placenta. 2021: 837–867.
  12. Martínez-Ibarra A, Martínez-Razo LD, Vázquez-Martínez ER, et al. Unhealthy Levels of Phthalates and Bisphenol A in Mexican Pregnant Women with Gestational Diabetes and Its Association to Altered Expression of miRNAs Involved with Metabolic Disease. Int J Mol Sci. 2019; 20(13).
  13. Hromadnikova I, Kotlabova K, Ivankova K, et al. First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR. PLoS One. 2017; 12(2): e0171756.
  14. Bounds KR, Chiasson VL, Pan LuJ, et al. MicroRNAs: New Players in the Pathobiology of Preeclampsia. Front Cardiovasc Med. 2017; 4: 60.
  15. von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4): 344–349.
  16. Jaszczuk I, Koczkodaj D, Kondracka A, et al. The role of miRNA-210 in pre-eclampsia development. Ann Med. 2022; 54(1): 1350–1356.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl